



## Our Business Objectives

Canadian International Pharma Corp. ("CIPC" or the "Company") is an emerging multi-faceted pharmaceutical company that is in the process of developing generic and Nutraceutical drug manufacturing, distribution and sales. CIPC has recently entered into a letter of intent to license the formulations of 99 generic and nutraceutical and medications. Upon completion of a definitive agreement, and any regulatory approvals, the Company intends to pursue commercial agreements to produce and sell these medications. CIPC has also recently launched its PharmaCert Program. PharmaCert is a certification program for testing and measuring finished dosage forms of generic and nutraceutical medications. The Company has also aligned itself with Canadian and US manufacturers with the objective of manufacturing its medications for Canadian and overseas markets.

## The Services We are Developing

A certification program for testing and measuring finished dosage forms of Nutraceutical and pharmaceutical medications.

## Management and Directors

- Dr. Mack Payravi, Pharm.D., MBA  
*President*
- Douglas Mason  
*Chairman and CEO*
- Andrzej Kowalski, B.A., LL.B., LL.M  
*Business Development*
- Sead Hamzagic, CPA-CGA  
*Chief Financial Officer*

## Manufacturing

The Company has aligned itself with Canadian and US manufacturers with the objective of manufacturing generics and nutraceuticals for Canadian and overseas markets, packaging, finished dose form and more.



## Advisory Board

- Doug Patterson, B.Sc.(Pharmacy)  
*Chair*
- Aaron Wong, B.Sc.(Pharmacy)  
*Board Member*

## Cross Licensing



CIPC cross licenses generic and nutraceutical medications manufactured by international companies. We provide services to register these medications in North American markets. Once registered, CIPC offers sales and marketing programs to promote these medications in Canadian and US markets.

## Fundamentals: as of September 12, 2016

Exchange	TSXV NEX Board
Symbol	CIP.H
Shares Outstanding	32,873,013
Share Price	0.11
Market Capitalization	\$3.6 million
52 week range (high/low)	\$0.15-\$0.055
Management & Board Shareholdings	24%

Canadian International Pharma Corp. launches PharmaCert Certification Program, a medication certification program using globally respected Canadian and US standards

### Canadian International Pharma Corp. Launches PharmaCert Certification Program

**April 25, 2016 – Canadian International Pharma Corp.** announced that it has launched the PharmaCert Certification Program, a medication certification program using globally respected Canadian and US standards that measure the identity, strength, quality and purity of medications based on trusted standards, such as United States Pharmacopeia and British Pharmacopeia.

PharmaCert can be used to certify any class of nutraceutical and pharmaceutical medications. Testing certifies that the ingredients claimed on the label and the formulation of the medication exist in the final product and that each ingredient has the concentration and potency as claimed on the product label. Thus assuring its quality, safety, bioavailability and efficacy. The PharmaCert certification also ensures there are no unwanted, toxic or harmful ingredients in the tested medications. The PharmaCert certification assures consumers and government regulators in each country that the medication adheres to the highest level of standards and “GMP” (good manufacturing practices), as found in Canada and the US. For more information, visit [www.pharmacert.ca](http://www.pharmacert.ca)

“The PharmaCert Certification Program was developed to provide medication and nutraceutical manufacturers, distributors and government regulators in developing countries the opportunity for their locally manufactured drugs to compete with national brands. We are pleased with the response we have received to date for this certification program. Stakeholders are recognizing how PharmaCert differentiates locally manufactured medications in their local and export markets from competing medications and national brands in a very positive way.” said Douglas L. Mason, CEO of Canadian International Pharma Corp.



Canadian International  
**Pharma Corp.**  
[www.canpharmacorp.ca](http://www.canpharmacorp.ca)  
2489 Bellevue Avenue  
West Vancouver, BC V7V 1E1 Canada  
Tel +1.604.922.2030

### Contact Us

Dr. Mack Payravi, Pharm. D., MBA  
*President*  
+1.604.362.4146  
[mack@canpharmacorp.ca](mailto:mack@canpharmacorp.ca)

Douglas Mason  
*Chairman and CEO*  
+1.604.922.2030  
[dmason@canpharmacorp.ca](mailto:dmason@canpharmacorp.ca)

### Canadian International Pharma Corp. Provides Company Update

**September 15, 2016 – Canadian International Pharma Corp.** provides an update on the Company’s ongoing efforts to grow its business and to generate shareholder value.

#### PharmaCert Program

One of CIPC’s major focusses is its PharmaCert Program. PharmaCert is a Canadian certification program for finished dosage forms of nutraceutical and pharmaceutical medications manufactured around the world. To date, CIPC has received two expressions of interest from major international manufacturers through its online registration system. The Company is working closely with these two manufacturers in an effort to enter into contracts to provide the PharmaCert Program for their multiple medications. For more information about the PharmaCert program, visit the company’s dedicated website at [www.pharmacert.ca](http://www.pharmacert.ca)

#### Cross Licensing

CIPC cross licenses generic and nutraceutical medications manufactured by international companies. The company can provide services to register these medications in North American markets. Once registered, CIPC offers sales and marketing programs to promote these medications in Canadian and US markets.

#### Business Development Agents

As part of its plan to develop and generate generic and nutraceutical sales for the Company, CIPC is actively engaging independent sales agents in strategic regions worldwide. To date, the Company has engaged 5 Business Development Agents covering the Middle East, Europe, Dubai, Iran, Egypt and India, and will continue to engage qualified agents that can provide resources and quality business contacts to develop sales in new territories.

*FORWARD LOOKING STATEMENTS: These materials include certain statements that may be deemed “forward-looking statements” within the meaning of applicable securities legislation. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “suspects”, “intends”, “estimates”, “projects”, “targets”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those expressed in, or implied by, this forward looking information. Factors that could cause actual results to differ materially from those in forward-looking statements include such matters as market prices for the Company’s anticipated products, regulatory approvals required for the Company’s business plans, continued availability of capital and financing, and general economic, market or business conditions. Any forward-looking statements are expressly qualified in their entirety by this cautionary statement. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date such statements were made. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*